Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Carrie A. Adelman"'
Autor:
Natalia Lukashchuk, Alan Barnicle, Carrie A. Adelman, Joshua Armenia, Jinyu Kang, J. Carl Barrett, Elizabeth A. Harrington
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Prostate cancer is among the most common diseases worldwide. Despite recent progress with treatments, patients with advanced prostate cancer have poor outcomes and there is a high unmet need in this population. Understanding molecular determinants un
Externí odkaz:
https://doaj.org/article/75ddc3fc85e340e5abec988d20c8dc6f
Autor:
Kim N. Chi, Alan Barnicle, Caroline Sibilla, Zhongwu Lai, Claire Corcoran, J. Carl Barrett, Carrie A. Adelman, Ping Qiu, Ashley Easter, Simon Dearden, Geoffrey R. Oxnard, Neeraj Agarwal, Arun Azad, Johann de Bono, Joaquin Mateo, David Olmos, Antoine Thiery-Vuillemin, Elizabeth A. Harrington
Publikováno v:
Scientia
Purpose: Not all patients with metastatic castration-resistant prostate cancer (mCRPC) have sufficient tumor tissue available for multigene molecular testing. Furthermore, samples may fail because of difficulties within the testing procedure. Optimiz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::050ebcc8565fcfee7b8aae811ea910d3
https://doi.org/10.1158/1078-0432.ccr-22-0931
https://doi.org/10.1158/1078-0432.ccr-22-0931
Autor:
Guochang Huang, Andrew J Kaufman, Russell J H Ryan, Yevgeniy Romin, Laryssa Huryn, Sarina Bains, Katia Manova-Todorova, Patricia L Morris, Gary R Hunnicutt, Carrie A Adelman, John H J Petrini, Y Ramanathan, Bhuvanesh Singh
Publikováno v:
PLoS ONE, Vol 14, Iss 1, p e0209995 (2019)
Squamous cell carcinoma-related oncogene (SCCRO, also known as DCUN1D1) is a component of the E3 for neddylation. As such, DCUN1D1 regulates the neddylation of cullin family members. Targeted inactivation of DCUN1D1 in mice results in male-specific i
Externí odkaz:
https://doaj.org/article/b2c5cb5ef6f94ce8bb3cf00f8422e4c2
Autor:
Elizabeth A. Harrington, Antoine Thiery-Vuillemin, David Olmos, Joaquin Mateo, Johann de Bono, Arun Azad, Neeraj Agarwal, Geoffrey R. Oxnard, Simon Dearden, Ashley Easter, Ping Qiu, Carrie A. Adelman, J. Carl Barrett, Claire Corcoran, Zhongwu Lai, Caroline Sibilla, Alan Barnicle, Kim N. Chi
Supplementary Figure from Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19d5154ea363820d2a4c6b4547cf8579
https://doi.org/10.1158/1078-0432.22489499
https://doi.org/10.1158/1078-0432.22489499
Autor:
Elizabeth A. Harrington, Antoine Thiery-Vuillemin, David Olmos, Joaquin Mateo, Johann de Bono, Arun Azad, Neeraj Agarwal, Geoffrey R. Oxnard, Simon Dearden, Ashley Easter, Ping Qiu, Carrie A. Adelman, J. Carl Barrett, Claire Corcoran, Zhongwu Lai, Caroline Sibilla, Alan Barnicle, Kim N. Chi
Supplementary Data from Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49b80c4653e0a112e4f527cdf528960b
https://doi.org/10.1158/1078-0432.22489511.v1
https://doi.org/10.1158/1078-0432.22489511.v1
Autor:
Elizabeth A. Harrington, Antoine Thiery-Vuillemin, David Olmos, Joaquin Mateo, Johann de Bono, Arun Azad, Neeraj Agarwal, Geoffrey R. Oxnard, Simon Dearden, Ashley Easter, Ping Qiu, Carrie A. Adelman, J. Carl Barrett, Claire Corcoran, Zhongwu Lai, Caroline Sibilla, Alan Barnicle, Kim N. Chi
Purpose:Not all patients with metastatic castration-resistant prostate cancer (mCRPC) have sufficient tumor tissue available for multigene molecular testing. Furthermore, samples may fail because of difficulties within the testing procedure. Optimiza
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81b6756b0eb67a2c94a85a2c40da3c04
https://doi.org/10.1158/1078-0432.c.6532970.v1
https://doi.org/10.1158/1078-0432.c.6532970.v1
Autor:
Johann de Bono, Christian Poehlein, Allison Allen, Carrie A. Adelman, Jinyu Kang, Julia A. Elvin, Robert Huisden, Alexander Kohlmann, Charles Padua, Young Deuk Choi, Craig Gedye, Nobuaki Matsubara, Mustafa Özgüroǧlu, Guilhem Roubaud, Michael P. Kolinsky, Niven Mehra, David Olmos, Joaquin Mateo, Shahneen Sandhu, Neal Shore, Fred Saad, Karim Fizazi, Caroline Sibilla, Claire Corcoran, Maha Hussain
Supplementary Figure from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16d8c245523421431a9963e0bfaf8fc9
https://doi.org/10.1158/1078-0432.22486373
https://doi.org/10.1158/1078-0432.22486373
Autor:
Johann de Bono, Christian Poehlein, Allison Allen, Carrie A. Adelman, Jinyu Kang, Julia A. Elvin, Robert Huisden, Alexander Kohlmann, Charles Padua, Young Deuk Choi, Craig Gedye, Nobuaki Matsubara, Mustafa Özgüroǧlu, Guilhem Roubaud, Michael P. Kolinsky, Niven Mehra, David Olmos, Joaquin Mateo, Shahneen Sandhu, Neal Shore, Fred Saad, Karim Fizazi, Caroline Sibilla, Claire Corcoran, Maha Hussain
Purpose:Successful implementation of genomic testing in clinical practice is critical for identification of men with metastatic castration-resistant prostate cancer (mCRPC) eligible for olaparib and future molecularly targeted therapies.Patients and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0af4a5f059d9d09c98a4b55d79bc2c7e
https://doi.org/10.1158/1078-0432.c.6532301
https://doi.org/10.1158/1078-0432.c.6532301
Autor:
Johann de Bono, Christian Poehlein, Allison Allen, Carrie A. Adelman, Jinyu Kang, Julia A. Elvin, Robert Huisden, Alexander Kohlmann, Charles Padua, Young Deuk Choi, Craig Gedye, Nobuaki Matsubara, Mustafa Özgüroǧlu, Guilhem Roubaud, Michael P. Kolinsky, Niven Mehra, David Olmos, Joaquin Mateo, Shahneen Sandhu, Neal Shore, Fred Saad, Karim Fizazi, Caroline Sibilla, Claire Corcoran, Maha Hussain
Supplementary Data from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c48c97fd7383dece78bda46f6ef6b73
https://doi.org/10.1158/1078-0432.22486391.v1
https://doi.org/10.1158/1078-0432.22486391.v1
Autor:
Maha Hussain, Claire Corcoran, Caroline Sibilla, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Joaquin Mateo, David Olmos, Niven Mehra, Michael P. Kolinsky, Guilhem Roubaud, Mustafa Özgüroǧlu, Nobuaki Matsubara, Craig Gedye, Young Deuk Choi, Charles Padua, Alexander Kohlmann, Robert Huisden, Julia A. Elvin, Jinyu Kang, Carrie A. Adelman, Allison Allen, Christian Poehlein, Johann de Bono
Publikováno v:
Clinical Cancer Research, 28, 8, pp. 1518-1530
Clinical Cancer Research, 28, 1518-1530
Clinical Cancer Research, 28, 1518-1530
Purpose: Successful implementation of genomic testing in clinical practice is critical for identification of men with metastatic castration-resistant prostate cancer (mCRPC) eligible for olaparib and future molecularly targeted therapies. Patients an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6e6465762b78cfec9e83793e21446e7
https://repository.ubn.ru.nl/handle/2066/249794
https://repository.ubn.ru.nl/handle/2066/249794